Comparative Pharmacology
Head-to-head clinical analysis: SULFAMYLON versus TRIPLE SULFAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAMYLON versus TRIPLE SULFAS.
SULFAMYLON vs TRIPLE SULFAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamylon (mafenide acetate) is a synthetic sulfonamide that exerts bacteriostatic activity against a wide range of Gram-negative and Gram-positive organisms. It acts by inhibiting the enzyme dihydropteroate synthase, which is involved in folate synthesis, thereby blocking bacterial DNA replication. Additionally, it may be bactericidal at high concentrations via inhibition of cell wall synthesis.
Competitive inhibition of dihydropteroate synthase, thereby blocking folate synthesis and bacterial DNA replication. Triple sulfas (sulfadiazine, sulfamerazine, sulfamethazine) act synergistically to inhibit folic acid synthesis.
Topical: Apply a thin layer to the wound once or twice daily. Maximum coverage area should not exceed body surface area of 20%.
1 to 2 tablets (each containing sulfadiazine 167 mg, sulfamerazine 167 mg, sulfamethazine 167 mg) orally every 4 hours initially, then 2 tablets every 6 hours. Maximum daily dose: 6 grams of total sulfonamide.
None Documented
None Documented
The terminal elimination half-life is approximately 7-8 hours in patients with normal renal function. In renal impairment, half-life may be prolonged, requiring dosing adjustments.
Terminal elimination half-life ranges from 10-12 hours in adults with normal renal function. Prolonged in renal impairment (up to 24-48 hours) and neonates (40-120 hours).
Primarily renal excretion as unchanged drug and its metabolite; approximately 87% of a dose is recovered in urine within 24 hours as sulfacetamide and its deacetylated metabolite, with about 10% as unchanged drug. Less than 2% is excreted in feces.
Primarily renal; approximately 70-100% excreted unchanged in urine via glomerular filtration and tubular secretion. Minor biliary/fecal elimination (<5%) with enterohepatic circulation possible.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic